Today's Daily Dose brings you news about an update on Acasti Pharma's TRILOGY 2 study, Biohaven's disappointing results from Generalized Anxiety Disorder trial, Aquestive Therapeutics' date with FDA, the clinical hold on LogicBio Therapeutics' methylmalonic acidemia trial and Mereo BioPharma's funding transactions.
Original Article: ACST Plunges On Data Delay, MREO On Watch, AQST Faces FDA In Sep.